Prevention and Treatment of Alzheimer's Disease
neuroscienceCME WebcastPremiere Date: Thursday, December 8, 2016
This activity offers CE credit for:%>
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, December 8, 2017
Note: Credit Is No Longer Available
|Davangere P. Devanand, MD
Professor of Psychiatry and Neurology
Director, Division of Geriatric Psychiatry
Columbia University Medical Center
New York, NY
This video is a replay of a plenary session from the 9th Annual Chair Summit Master Class for Neuroscience Professional Development held in Miami, Florida on September 15 – 17, 2016.
At the end of this CE activity, participants should be able to:
- Identify patients who are candidates for early intervention with treatment for Alzheimer’s disease.
- Incorporate advances in technology, including imaging and biomarkers when appropriate, to improve diagnosis and monitor disease progression in AD.
- Translate the evolving science about the role of current and emerging therapies for the clinical management of AD.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Physicians, physician assistants, nurse practitioners, and other health care professionals with an interest in psychiatry, neurology, and the neurosciences.
CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Devanand has disclosed he receives research support from Avanir Pharmaceuticals, Inc. He is a consultant for AbbVie Inc.; Astellas Pharma Inc.; Intra-cellular Therapies, Inc.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report .
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).